Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGD | P15428 | 2/20 | 0.62 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.62 |
| ▸ | PARP1 | P09874 | 1/20 | 0.57 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.53 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.50 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.49 |
| ▸ | KCNK9 | Q9NPC2 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.49 |
| ▸ | POLB | P06746 | 2/20 | 0.47 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | HSD17B2 | P37059 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279166 | 0.87 | KMT2A (0.53) | HPGDTDP1HDAC8HDAC6MEN1 | |
| SCHEMBL29637011 | 0.86 | HPGD (0.65) | HPGDTDP1PARP1HDAC8HDAC6 | |
| SCHEMBL23782 | 0.86 | HPGD (0.65) | HPGDTDP1PARP1HDAC8HDAC6 | |
| SCHEMBL1759401 | 0.86 | HPGD (0.65) | HPGDTDP1PARP1HDAC8HDAC6 | |
| SCHEMBL6832775 | 0.82 | HPGD (0.61) | HPGDTDP1PARP1HDAC8HDAC6 | |
| SCHEMBL9100257 | 0.82 | HPGD (0.61) | HPGDTDP1PARP1HDAC8HDAC6 | |
| SCHEMBL11913144 | 0.81 | HPGD (0.74) | HPGDTDP1PARP1HDAC8HDAC6 | |
| SCHEMBL25908515 | 0.80 | HPGD (0.62) | HPGDTDP1PARP1HDAC8HDAC6 | |
| SCHEMBL11675937 | 0.80 | HPGD (0.62) | HPGDTDP1PARP1HDAC8HDAC6 | |
| SCHEMBL3658429 | 0.79 | HPGD (0.62) | HPGDTDP1PARP1HDAC8HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1461010-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | Integriderm, Inc. (US) | 2004-09-29 | — | — | EP | claimed |
| US-20030199558-A1 | Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners | INTEGRIDERM, INC. | 2003-10-23 | — | — | US | claimed |
| WO-2003057184-A2 | HYDROXAMIC ACID AND ITS DERIVATIVES AS INHIBITORS OF MELANOCYTE TYROSINASE FOR TOPICAL SKIN LIGHTENERS | INTEGRIDERM, INC. (US) | 2003-07-17 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030199558-A1 | Hydroxamic acid and its derivatives as inhibitors of melanocyte tyrosinase for topical skin lighteners | TYR, MC1R, MITF | HPGD 131/4885TDP1 2112/4885PARP1 4014/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.